The pharma stock is up around 17% this year.
GlobalData on MSN
Vertex signs agreement to acquire Crinetics for $10bn
The acquisition is expected to close in the third quarter of 2026.
Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it ...
The transaction's two focuses, Palsonify and atumelnant, have combined peak sales potential of more than $5 billion, Vertex ...
The Boston-based drugmaker has been on a mission to build out the next generation of drug products beyond its cystic fibrosis ...
With expected close this quarter, the stock should converge toward the deal price as deal certainty rises and spreads tighten ...
Vertex Pharmaceuticals will buy Crinetics Pharmaceuticals for a total equity value of about $10 billion, the companies said on Monday.
Transaction terms include $85-per-share all-cash consideration (~$10B enterprise value) and an anticipated Q3 2026 close, contingent on customary conditions. Portfolio fit emphasizes serious, ...
Vertex Pharmaceuticals to acquire Crinetics (CRNX) for $10 billion in all-cash deal at $85 per share, gaining key ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...
An announcement from Crinetics Pharmaceuticals ( (CRNX)) is now available. On July 6, 2026, Vertex Pharmaceuticals and Crinetics Pharmaceuticals signed a definitive merger agreement under which Vertex ...
Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results